Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company focused on central nervous system (CNS) diseases, has announced its plans to report second quarter 2024 financial and business results on August 6, 2024, after market close. The company will host a conference call at 4:30 p.m. ET on the same day, featuring Jack Khattar, President and CEO, and Tim Dec, Senior VP and CFO.
A live webcast will be available on the company's Investor Relations website. Participants can pre-register for the call and will receive a personalized dial-in number. The webcast replay will be accessible on the website for 60 days following the live call.
Supernus Pharmaceuticals (Nasdaq: SUPN), un'azienda biofarmaceutica focalizzata sulle malattie del sistema nervoso centrale (CNS), ha annunciato i suoi piani per riportare i risultati finanziari e aziendali del secondo trimestre 2024 il 6 agosto 2024, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica alle 16:30 ET dello stesso giorno, con la partecipazione di Jack Khattar, Presidente e CEO, e Tim Dec, VP senior e CFO.
Un webcast dal vivo sarà disponibile sul sito web delle Relazioni con gli Investitori dell'azienda. I partecipanti possono pre-registrarsi per la chiamata e riceveranno un numero di accesso personalizzato. La registrazione del webcast sarà accessibile sul sito web per 60 giorni dopo la chiamata dal vivo.
Supernus Pharmaceuticals (Nasdaq: SUPN), una empresa biofarmacéutica centrada en las enfermedades del sistema nervioso central (CNS), ha anunciado sus planes para informar sobre los resultados financieros y comerciales del segundo trimestre de 2024 el 6 de agosto de 2024, después del cierre del mercado. La compañía llevará a cabo una conferencia telefónica a las 4:30 p.m. ET el mismo día, con la participación de Jack Khattar, Presidente y CEO, y Tim Dec, VP senior y CFO.
Habrá un webcast en vivo disponible en el sitio web de Relaciones con Inversores de la empresa. Los participantes pueden pre-registrarse para la llamada y recibirán un número de acceso personalizado. La grabación del webcast estará disponible en el sitio web durante 60 días después de la llamada en vivo.
슈퍼너스 제약 (Nasdaq: SUPN)은 중추신경계(CNS) 질환에 중점을 둔 생물의약품 회사로, 2024년 2분기 재무 및 사업 결과를 2024년 8월 6일에 시장 종료 후 발표할 계획이라고 밝혔습니다. 회사는 같은 날 오후 4:30 ET에 Jack Khattar 사장 겸 CEO와 Tim Dec 수석 부사장 겸 CFO가 참석하는 전화 회의를 개최할 예정입니다.
실시간 웹캐스트는 회사의 투자자 관계 웹사이트에서 제공됩니다. 참여자는 회의에 사전 등록할 수 있으며 개인화된 다이얼인 번호를 받을 수 있습니다. 웹캐스트 재생은 실시간 통화 후 60일 동안 웹사이트에서 액세스할 수 있습니다.
Supernus Pharmaceuticals (Nasdaq: SUPN), une entreprise biopharmaceutique axée sur les maladies du système nerveux central (CNS), a annoncé ses projets de présenter les résultats financiers et commerciaux du deuxième trimestre 2024 le 6 août 2024, après la fermeture du marché. L'entreprise organisera une conférence téléphonique le même jour à 16h30 ET, avec Jack Khattar, Président et PDG, et Tim Dec, VP senior et CFO.
Un webinaire en direct sera disponible sur le site Web des Relations avec les Investisseurs de l'entreprise. Les participants peuvent se préinscrire pour l'appel et recevront un numéro d'accès personnalisé. La rediffusion du webinaire sera accessible sur le site pendant 60 jours après l'appel en direct.
Supernus Pharmaceuticals (Nasdaq: SUPN), ein biopharmazeutisches Unternehmen, das sich auf Erkrankungen des zentralen Nervensystems (CNS) konzentriert, hat seine Pläne angekündigt, die Finanz- und Geschäftsergebnisse für das zweite Quartal 2024 am 6. August 2024 nach Börsenschluss zu berichten. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz veranstalten, an der Jack Khattar, Präsident und CEO, sowie Tim Dec, Senior VP und CFO, teilnehmen werden.
Ein Live-Webcast wird auf der Investor-Relations-Website des Unternehmens verfügbar sein. Teilnehmer können sich im Voraus für die Konferenz registrieren und erhalten eine personalisierte Einwahlnummer. Der Webcast wird 60 Tage nach der Live-Konferenz auf der Website verfügbar sein.
- None.
- None.
ROCKVILLE, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2024 after the market closes on Tuesday, August 6, 2024.
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the second quarter 2024 financial and business results on Tuesday, August 6, 2024 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.
A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/Investors.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/Investors. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
FAQ
When will Supernus Pharmaceuticals (SUPN) release its Q2 2024 financial results?
What time is Supernus Pharmaceuticals' (SUPN) Q2 2024 earnings call scheduled for?
Who will be hosting Supernus Pharmaceuticals' (SUPN) Q2 2024 earnings call?
Where can I access the webcast for Supernus Pharmaceuticals' (SUPN) Q2 2024 earnings call?
